| __timestamp | Apellis Pharmaceuticals, Inc. | Taro Pharmaceutical Industries Ltd. |
|---|---|---|
| Wednesday, January 1, 2014 | 2908166 | 91733000 |
| Thursday, January 1, 2015 | 6356782 | 87644000 |
| Friday, January 1, 2016 | 4303743 | 92365000 |
| Sunday, January 1, 2017 | 10463151 | 85656000 |
| Monday, January 1, 2018 | 22639184 | 88196000 |
| Tuesday, January 1, 2019 | 67046483 | 89971000 |
| Wednesday, January 1, 2020 | 139401000 | 93413000 |
| Friday, January 1, 2021 | 176771000 | 91355000 |
| Saturday, January 1, 2022 | 277163000 | 113676000 |
| Sunday, January 1, 2023 | 500815000 | 198366000 |
| Monday, January 1, 2024 | 218935000 |
Data in motion
In the ever-evolving pharmaceutical industry, operational costs play a pivotal role in shaping a company's financial health. This analysis delves into the Selling, General, and Administrative (SG&A) expenses of Apellis Pharmaceuticals, Inc. and Taro Pharmaceutical Industries Ltd. over the past decade. From 2014 to 2023, Apellis Pharmaceuticals witnessed a staggering increase in SG&A expenses, skyrocketing from approximately $3 million to over $500 million, marking a growth of over 16,000%. In contrast, Taro Pharmaceutical Industries maintained a more stable trajectory, with expenses fluctuating between $86 million and $219 million, reflecting a more conservative growth pattern. This stark contrast highlights Apellis's aggressive expansion strategy, while Taro's steady approach underscores its focus on sustainable growth. As we look to the future, these trends offer valuable insights into the strategic priorities of these industry leaders.
Takeda Pharmaceutical Company Limited vs Apellis Pharmaceuticals, Inc.: SG&A Expense Trends
Comparing SG&A Expenses: argenx SE vs Apellis Pharmaceuticals, Inc. Trends and Insights
Breaking Down SG&A Expenses: United Therapeutics Corporation vs Apellis Pharmaceuticals, Inc.
Ionis Pharmaceuticals, Inc. vs Apellis Pharmaceuticals, Inc.: SG&A Expense Trends
Apellis Pharmaceuticals, Inc. and ImmunityBio, Inc.: SG&A Spending Patterns Compared
Apellis Pharmaceuticals, Inc. or Soleno Therapeutics, Inc.: Who Manages SG&A Costs Better?
Cost Management Insights: SG&A Expenses for Apellis Pharmaceuticals, Inc. and Evotec SE
CRISPR Therapeutics AG or Taro Pharmaceutical Industries Ltd.: Who Manages SG&A Costs Better?
Comparing SG&A Expenses: PTC Therapeutics, Inc. vs Taro Pharmaceutical Industries Ltd. Trends and Insights
Who Optimizes SG&A Costs Better? MorphoSys AG or Taro Pharmaceutical Industries Ltd.
Vericel Corporation vs Taro Pharmaceutical Industries Ltd.: SG&A Expense Trends
Mesoblast Limited vs Taro Pharmaceutical Industries Ltd.: SG&A Expense Trends